Che Lingbin, Wang Ying, Sha Dongyong, Li Guangyi, Wei Ziheng, Liu Changsheng, Yuan Yuan, Song Dianwen
Department of Orthopedics, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200080, PR China.
Key Laboratory for Ultrafine Materials of Ministry of Education, Frontiers Science Center for Materiobiology and Dynamic Chemistry and School of Materials Science and Engineering, East China University of Science and Technology, Shanghai 200237, PR China.
Bioact Mater. 2022 Apr 5;19:75-87. doi: 10.1016/j.bioactmat.2022.03.023. eCollection 2023 Jan.
Osteoporosis is one of the most disabling consequences of aging, osteoporotic fractures and higher risk of the subsequent fractures leading to substantial disability and deaths, indicating both local fractures healing and the early anti-osteoporosis therapy are of great significance. Teriparatide is strong bone formation promoter effective in treating osteoporosis, while side effects limit clinical applications. Traditional drug delivery is lack of sensitive and short-term release, finding a new non-invasive and easily controllable drug delivery to not only repair the local fractures but also improve total bone mass has remained a great challenge. Thus, bioinspired by the natural bone components, we develop appropriate interactions between inorganic biological scaffolds and organic drug molecules, achieving both loaded with the teriparatide in the scaffold and capable of releasing on demand. Herein, biomimetic bone microstructure of mesoporous bioglass, a near-infrared ray triggered switch, thermosensitive liposomes based on a valve, and polydopamine coated as a heater is developed rationally for osteoporotic bone regeneration. Teriparatide is pulsatile released from intelligent delivery, not only rejuvenating osteoporotic bone defect, but also presenting strong systemic anti-osteoporosis therapy. This biomimetic bone carrying novel drug delivery platform is well worth expecting to be a new promising strategy and clinically commercialized to help patients survive from the osteoporotic fracture.
骨质疏松症是衰老最具致残性的后果之一，骨质疏松性骨折以及随后发生骨折的较高风险会导致严重残疾和死亡，这表明局部骨折愈合和早期抗骨质疏松治疗都具有重要意义。特立帕肽是一种有效的治疗骨质疏松症的强大骨形成促进剂，但其副作用限制了其临床应用。传统的药物递送缺乏灵敏的短期释放，找到一种新的非侵入性且易于控制的药物递送方式，既能修复局部骨折又能改善骨总量，仍然是一个巨大的挑战。因此，受天然骨成分的启发，我们开发了无机生物支架与有机药物分子之间的适当相互作用，实现了在支架中负载特立帕肽并能够按需释放。在此，合理开发了具有介孔生物玻璃的仿生骨微结构、基于阀门的近红外线触发开关、热敏脂质体以及作为加热器的聚多巴胺涂层，用于骨质疏松性骨再生。特立帕肽从智能递送系统中脉冲式释放，不仅能使骨质疏松性骨缺损恢复活力，还能提供强大的全身抗骨质疏松治疗。这种携带新型药物递送平台的仿生骨很值得期待成为一种新的有前景的策略并实现临床商业化，以帮助患者从骨质疏松性骨折中康复。
